Page last updated: 2024-12-06

olaflur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Olaflur: cariostatic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23257
CHEMBL ID2106575
SCHEMBL ID120874
MeSH IDM0479677

Synonyms (51)

Synonym
2,2'-((3-(2-hydroxyethyl) octadecylamino)propyl) iminodiethanol dihydrofluoride
skf 38095j2
n,n,n-tris(2-hydroxyethyl)-n-octadecyl-1,3-diaminopropane dihydrofluoride
amine fluoride 297
skf 38095
2,2'-((3-((2-hydroxyethyl)octadecylamino)propyl)imino)diethanol dihydrofluoride
olaflurum [inn-latin]
olaflur [usan:inn:ban]
ethanol, 2,2'-((3-((2-hydroxyethyl)octadecylamino)propyl)imino)bis-, dihydrofluoride
bis-hydroxyaethylaminopropyl-hydroxyaethyl-octadecylamindihydrofluorid [german]
ga 297
c-27-amine fluoride
propane, n,n,n-tris(2-hydroxyethyl)-n-octadecyl-1,3-diamino-, dihydrofluoride
stearyl trihydroxyethyl propylenediamine dihydrofluoride
ethanol, 2,2'-((3-(n-(2-hydroxyethyl)-n-octadecylamino)propyl)imino)di-, dihydrofluoride
olaflur
bishydroxyethylaminepropyl-n-hydroxyethyloctadecylamine-dihydrofluoride
einecs 229-891-6
olaflurum [latin]
D05241
6818-37-7
olaflur (usan/inn)
bis(hydroxyethyl)-aminopropyl-n-hydroxyethyl-octadecylamine dihydrofluoride
olafur
skf-38095
CHEMBL2106575
bis(hydroxyethylaminopropyl)-n-hydroxyethyloctadecylamine dihydrofluoride
unii-8ny9l8837d
olaflurum
elmex gelee
sk&f 38095
8ny9l8837d ,
bis-hydroxyaethylaminopropyl-hydroxyaethyl-octadecylamindihydrofluorid
n-octadecyltrimethylenediamine-n,n,n'-tris(2-ethanol)dihydrofluoride
SCHEMBL120874
olaflur [mi]
olaflur [mart.]
olaflur [inci]
olaflur [who-dd]
sk&f-38095
olaflur [inn]
olaflur [usan]
c27-amine fluoride
2,2'-(3-((2-hydroxyethyl)(octadecyl)amino)propylazanediyl)diethanol dihydrofluoride
2,2'-({3-[(2-hydroxyethyl)(octadecyl)amino]propyl}azanediyl)di(ethan-1-ol)--hydrogen fluoride (1/2)
DTXSID40987684
FT-0714322
DB13290
Q263284
2,2'-((3-((2-hydroxyethyl)(octadecyl)amino)propyl)azanediyl)diethanol dihydrofluoride
2-[3-[bis(2-hydroxyethyl)amino]propyl-octadecylamino]ethanol;dihydrofluoride

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The results indicate that mucin in combination with various fluorides seems to affect enamel remineralization significantly."( Effect of mucin alone and in combination with various dentifrices on in vitro Remineralization.
Hopfenmuller, W; Kielbassa, AM; Meyer-Lueckel, H; Umland, N,
)
0.13
" The aim of this in vitro study was to evaluate the effects of fluoride mouthrinses or gels in combination with de-/remineralizing saliva substitutes on dentinal subsurface lesions."( Mineral distribution of artificial dentinal caries lesions after treatment with fluoride agents in combination with saliva substitutes.
Meyer-Lueckel, H; Tschoppe, P, 2011
)
0.37
"Under the in vitro conditions chosen, use of fluoride agents in combination with a demineralizing saliva substitute resulted in reduced mineral loss."( Mineral distribution of artificial dentinal caries lesions after treatment with fluoride agents in combination with saliva substitutes.
Meyer-Lueckel, H; Tschoppe, P, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of F from four dentifrices with either aminefluoride (AMF) or monofluorophosphate (MFP) was compared with that of NaF."( Human plasma fluoride levels following intake of dentifrices containing aminefluoride or monofluorophosphate.
Einwag, J; Trautner, K, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
"Test products were: new dentifrice formulation in a fluoride dose-response (0; 675; 1426 ppm F as sodium fluoride [NaF-0; NaF-675; NaF]); Elmex Kariesschutz (1400 ppm F as amine fluoride [AmF]); and Oral-B Pro-Expert (1450 ppm F-1100 ppm F as stannous fluoride and 350 ppm F as sodium fluoride [SnNaF])."( Laboratory assessment of the anticaries potential of a new dentifrice.
Chauhan, VK; Lippert, F; Lynch, RJ; Newby, EE; Schemehorn, BR, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (35.54)18.7374
1990's16 (9.64)18.2507
2000's43 (25.90)29.6817
2010's40 (24.10)24.3611
2020's8 (4.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.33 (24.57)
Research Supply Index5.44 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (32.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials39 (20.42%)5.53%
Reviews1 (0.52%)6.00%
Case Studies2 (1.05%)4.05%
Observational0 (0.00%)0.25%
Other149 (78.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months [NCT01329731]Phase 448 participants (Actual)Interventional2011-03-31Completed
Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients: Comparison of Different Toothbrushing Protocols [NCT00681135]118 participants (Actual)Interventional2008-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]